COST-UTILITY ANALYSIS OF TERIFLUNOMIDE IN NAIVE VS. PREVIOUSLY TREATED PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：0
|
作者：
Lazzaro, C. [1 ]
Bergamaschi, R. [2 ]
Zaffaroni, M. [3 ]
Totaro, R. [4 ]
Paolicelli, D. [5 ]
机构：
[1] Studio Econ Sanit, Milan, MI, Italy
[2] IRCCS Mondino Fdn, Pavia, Italy
[3] Hosp Gallarate, ASST Valle Olona, Multiple Sclerosis Ctr, Gallarate, Italy
[4] Osped San Salvatore, Ctr Malattie Demielinizzanti, Laquila, Italy
[5] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND45
引用
收藏
页码：S631 / S631
页数：1
相关论文
共 50 条
  • [21] Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Terzi, Murat
    Ozer, Bilge
    Turkoglu, Recai
    Karabudak, Rana
    Efendi, Husnu
    Soysal, Aysun
    Sevim, Serhan
    Altintas, Ayse
    Kurne, Asli
    Akcali, Aylin
    Akman, Gulsen
    Yuceyar, Nur
    Balci, Belgin Petek
    Ekmekci, Ozgul
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Altunrende, Burcu
    Turan, Omer Faruk
    GozubatikCelik, Gokcen
    Kale, Nilufer
    Koseoglu, Mesrure
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [22] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Mueller, J.
    Schaedelin, S.
    Benkert, P.
    Haenni, P.
    Schmid, J.
    Derfuss, T.
    Kuhle, J.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 676
  • [23] COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
    Silva Miguel, L.
    de Sa, J.
    Pinheiro, B.
    Acosta, C.
    VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
  • [24] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Ma, I
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
  • [25] Immunosuppresion following alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated With fingolimod
    Maria Cabrera-Maqueda, Jose
    Fuentes Rumi, Luna
    Valero Lopez, Gabriel
    Alba Isasi, Teresa
    Hernandez-Clares, Rocio
    Carreon Guarnizo, Ester
    Jimenez Veiga, Judith
    Iniesta-Martinez, Francisca
    Leon-Hernandez, Aida
    Zamarro Parra, Joaquin
    Morales Ortiz, Ana
    Meca Lallana, Jose
    NEUROLOGY, 2019, 92 (15)
  • [26] COST-UTILITY OF DISEASE MODIFYING THERAPIES FOR RELAPSING -REMITTING MULTIPLE SCLEROSIS
    Zimmermann, M.
    Brouwer, E.
    Tice, J. A.
    Seidner, M.
    Loos, A.
    Liu, S.
    Chapman, R. H.
    Kumar, V
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [27] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: the Chieti experience
    di Ioia, M.
    Travaglini, D.
    Di Tommaso, V.
    Mancinelli, L.
    Pietrolongo, E.
    De Luca, G.
    Farina, D.
    Lugaresi, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 754 - 754
  • [28] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review
    Gallehzan, Nasrin Abulhasanbeigi
    Khosravi, Majid
    Jamebozorgi, Khosro
    Mir, Nazanin
    Jalilian, Habib
    Soleimanpour, Samira
    Hoseini, Saeed
    Rezapour, Aziz
    Eshraghi, Abbas
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [29] Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
    Boz, C.
    Ozakbas, S.
    Terzi, M.
    Turkoglu, R.
    Akman, G.
    Efendi, H.
    Akcali, A.
    Tuncer, A.
    Yuceyar, N.
    Turan, O. F.
    Soysal, A.
    Koseoglu, M.
    Balci, B. P.
    Sevim, S.
    Altintas, A.
    Cilingir, V.
    Demirkiran, M.
    Kizilay, F.
    Altunrende, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 327 - 328
  • [30] Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis
    G. Kobelt
    L. Jönsson
    S. Fredrikson
    The European Journal of Health Economics, 2003, 4 (1) : 50 - 59
12345